PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions
Autor: | Jennifer le Guevelou, Vérane Achard, Ismini Mainta, Habib Zaidi, Valentina Garibotto, Igor Latorzeff, Paul Sargos, Cynthia Ménard, Thomas Zilli |
---|---|
Rok vydání: | 2021 |
Předmět: |
Biochemical recurrence
Cancer Research medicine.medical_specialty oligometastatic PET/CT fluciclovine medicine.medical_treatment Review RISK STRATIFICATION CLINICAL TARGET VOLUME Prostate cancer POSITRON-EMISSION-TOMOGRAPHY POSTOPERATIVE RADIOTHERAPY choline Prostate RADIATION-THERAPY PSMA medicine BIOCHEMICAL RECURRENCE DIAGNOSTIC-ACCURACY ADJUVANT RADIOTHERAPY RC254-282 radiotherapy relapse PET-CT medicine.diagnostic_test Prostatectomy business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens prostate cancer CONSENSUS GUIDELINES medicine.disease Radiation therapy PET medicine.anatomical_structure Oncology Prostate Bed Positron emission tomography ANDROGEN DEPRIVATION THERAPY Radiology business CT |
Zdroj: | Frontiers in Oncology Frontiers in Oncology, Vol 11 (2021) le Guevelou, J, Achard, V, Mainta, I, Zaidi, H, Garibotto, V, Latorzeff, I, Sargos, P, Ménard, C & Zilli, T 2021, ' PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy : Impact on Treatment Management and Future Directions ', Frontiers in Oncology, vol. 11, 742093 . https://doi.org/10.3389/fonc.2021.742093 |
ISSN: | 2234-943X |
Popis: | Biochemical recurrence is a clinical situation experienced by 20 to 40% of prostate cancer patients treated with radical prostatectomy (RP). Prostate bed (PB) radiation therapy (RT) remains the mainstay salvage treatment, although it remains non-curative for up to 30% of patients developing further recurrence. Positron emission tomography with computed tomography (PET/CT) using prostate cancer-targeting radiotracers has emerged in the last decade as a new-generation imaging technique characterized by a better restaging accuracy compared to conventional imaging. By adapting targeting of recurrence sites and modulating treatment management, implementation in clinical practice of restaging PET/CT is challenging the established therapeutic standards born from randomized controlled trials. This article reviews the potential impact of restaging PET/CT on changes in the management of recurrent prostate cancer after RP. Based on PET/CT findings, it addresses potential adaptation of RT target volumes and doses, as well as use of androgen-deprivation therapy (ADT). However, the impact of such management changes on the oncological outcomes of PET/CT-based salvage RT strategies is as yet unknown. |
Databáze: | OpenAIRE |
Externí odkaz: |